Review of the hardback: 'The pharmaceuticals industry presents a fascinating set of paradoxes. Dramatic advances in fundamental science have been associated with a wave of mergers among the leading pharmaceutical firms, the entry of small drug-discovery specialist firms, large increases in industry R&D spending and an apparent slowdown in the rate of innovation. This collection examines these paradoxes and derives important implications for our understanding of this science-based industry and for our understanding of industrial dynamics more generally. This volume will be of great interest to students of evolutionary economics, economic theorists and empirical researchers.' David C. Mowery, University of California - Berkeley